Ionis Pharmaceuticals (IONS) — insider trading
Health Care · NASDAQ
Ionis Pharmaceuticals (IONS) has 111 reported SEC Form 4 insider transactions in our data, including 2 open-market purchases and 24 open-market sales among the most recent 100 (latest 2026-08-31).
Recent Form 4 transactions
Showing the 100 most recent of 111 recorded transactions. See all on SEC EDGAR →
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | O'NEIL PATRICK R. | Officer (EVP CLO & General Counsel) | Other acquisition or disposition | 63 | $51.31 | $3.2K | Form 4 |
| 2026-08-31 | Monia Brett P | Director, Officer (Chief Executive Officer) | Other acquisition or disposition | 98 | $51.31 | $5.0K | Form 4 |
| 2026-08-31 | Birchler Brian | Officer (EVP, Corp and Development Ops) | Other acquisition or disposition | 58 | $51.31 | $3.0K | Form 4 |
| 2026-08-31 | BENNETT C FRANK | Officer (EVP, Chief Scientific Officer) | Other acquisition or disposition | 110 | $51.31 | $5.6K | Form 4 |
| 2026-07-31 | Hayden Michael R | Director | Open-market purchase | 5,000 | $51.60 | $258.0K | Form 4 |
| 2026-07-30 | Hayden Michael R | Director | Open-market purchase | 15,000 | $53.38 | $800.7K | Form 4 |
| 2026-07-15 | BERTHELSEN SPENCER R | Director | Option exercise / conversion (derivative) | 5,220 | — | $0 | Form 4 |
| 2026-07-15 | BERTHELSEN SPENCER R | Director | Option exercise / conversion | 5,220 | — | $0 | Form 4 |
| 2026-07-15 | HERMAN JOAN E | Director | Option exercise / conversion (derivative) | 5,220 | — | $0 | Form 4 |
| 2026-07-15 | HERMAN JOAN E | Director | Option exercise / conversion | 5,220 | — | $0 | Form 4 |
| 2026-07-15 | HANTSON LUDWIG | Director | Grant / award / vesting (derivative) | 3,399 | — | $0 | Form 4 |
| 2026-07-15 | Reikes Peter N | Director | Grant / award / vesting (derivative) | 3,399 | — | $0 | Form 4 |
| 2026-07-07 | Kordasiewicz Holly B. | Officer (EVP, Chief Development Officer) | Open-market sale | 362 | $84.30 | $30.5K | Form 4 |
| 2026-07-07 | Diaz Allene M. | Director | Option exercise / conversion (derivative) | 10,111 | — | $0 | Form 4 |
| 2026-07-07 | Diaz Allene M. | Director | Open-market sale | 10,111 | $85.42 | $863.6K | Form 4 |
| 2026-07-07 | Diaz Allene M. | Director | Option exercise / conversion | 10,111 | $47.11 | $476.3K | Form 4 |
| 2026-07-07 | BENNETT C FRANK | Officer (EVP, Chief Scientific Officer) | Other acquisition or disposition (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-07-07 | BENNETT C FRANK | Officer (EVP, Chief Scientific Officer) | Open-market sale | 15,000 | $85.46 | $1.28M | Form 4 |
| 2026-07-07 | BENNETT C FRANK | Officer (EVP, Chief Scientific Officer) | Other acquisition or disposition | 15,000 | — | $0 | Form 4 |
| 2026-07-07 | BENNETT C FRANK | Officer (EVP, Chief Scientific Officer) | Open-market sale | 5,536 | $83.58 | $462.7K | Form 4 |
| 2026-07-01 | BERTHELSEN SPENCER R | Director | Grant / award / vesting (derivative) | 2,301 | — | $0 | Form 4 |
| 2026-07-01 | BERTHELSEN SPENCER R | Director | Grant / award / vesting (derivative) | 5,369 | — | $0 | Form 4 |
| 2026-07-01 | Diaz Allene M. | Director | Grant / award / vesting (derivative) | 2,301 | — | $0 | Form 4 |
| 2026-07-01 | Diaz Allene M. | Director | Grant / award / vesting (derivative) | 5,369 | — | $0 | Form 4 |
| 2026-07-01 | Hayden Michael R | Director | Grant / award / vesting (derivative) | 2,301 | — | $0 | Form 4 |
| 2026-07-01 | Hayden Michael R | Director | Grant / award / vesting (derivative) | 5,369 | — | $0 | Form 4 |
| 2026-07-01 | KLEIN JOSEPH III | Director | Grant / award / vesting (derivative) | 2,301 | — | $0 | Form 4 |
| 2026-07-01 | KLEIN JOSEPH III | Director | Grant / award / vesting (derivative) | 5,369 | — | $0 | Form 4 |
| 2026-07-01 | KLEIN JOSEPH III | Director | Option exercise / conversion (derivative) | 11,518 | — | $0 | Form 4 |
| 2026-07-01 | KLEIN JOSEPH III | Director | Open-market sale | 11,419 | $79.04 | $902.6K | Form 4 |
| 2026-07-01 | KLEIN JOSEPH III | Director | Open-market sale | 99 | $79.45 | $7.9K | Form 4 |
| 2026-07-01 | KLEIN JOSEPH III | Director | Option exercise / conversion | 11,518 | $39.94 | $460.0K | Form 4 |
| 2026-07-01 | HERMAN JOAN E | Director | Grant / award / vesting (derivative) | 2,301 | — | $0 | Form 4 |
| 2026-07-01 | HERMAN JOAN E | Director | Grant / award / vesting (derivative) | 5,369 | — | $0 | Form 4 |
| 2026-07-01 | LOSCALZO JOSEPH | Director | Grant / award / vesting (derivative) | 2,301 | — | $0 | Form 4 |
| 2026-07-01 | LOSCALZO JOSEPH | Director | Grant / award / vesting (derivative) | 5,369 | — | $0 | Form 4 |
| 2026-07-01 | YANG MICHAEL J. | Director | Grant / award / vesting (derivative) | 2,301 | — | $0 | Form 4 |
| 2026-07-01 | YANG MICHAEL J. | Director | Grant / award / vesting (derivative) | 5,369 | — | $0 | Form 4 |
| 2026-06-26 | Schneider Eugene | Officer (EVP, Chf Clinical Develop Ofcr) | Option exercise / conversion (derivative) | 26,000 | — | $0 | Form 4 |
| 2026-06-26 | Schneider Eugene | Officer (EVP, Chf Clinical Develop Ofcr) | Open-market sale | 26,000 | $81.05 | $2.11M | Form 4 |
| 2026-06-26 | Schneider Eugene | Officer (EVP, Chf Clinical Develop Ofcr) | Option exercise / conversion | 26,000 | $60.89 | $1.58M | Form 4 |
| 2026-06-26 | O'NEIL PATRICK R. | Officer (EVP CLO & General Counsel) | Open-market sale | 3,069 | $80.00 | $245.5K | Form 4 |
| 2026-06-26 | Baroldi Joseph | Officer (EVP, Chief Business Officer) | Option exercise / conversion (derivative) | 3,866 | — | $0 | Form 4 |
| 2026-06-26 | Baroldi Joseph | Officer (EVP, Chief Business Officer) | Option exercise / conversion (derivative) | 1,769 | — | $0 | Form 4 |
| 2026-06-26 | Baroldi Joseph | Officer (EVP, Chief Business Officer) | Open-market sale | 5,635 | $80.16 | $451.7K | Form 4 |
| 2026-06-26 | Baroldi Joseph | Officer (EVP, Chief Business Officer) | Option exercise / conversion | 1,769 | $32.60 | $57.7K | Form 4 |
| 2026-06-26 | Baroldi Joseph | Officer (EVP, Chief Business Officer) | Option exercise / conversion | 3,866 | $56.78 | $219.5K | Form 4 |
| 2026-06-26 | Monia Brett P | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-06-26 | Monia Brett P | Director, Officer (Chief Executive Officer) | Open-market sale | 50,000 | $80.59 | $4.03M | Form 4 |
| 2026-06-26 | Monia Brett P | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 50,000 | $56.78 | $2.84M | Form 4 |
| 2026-06-25 | Swayze Eric | Officer (EVP Research) | Open-market sale | 10,602 | $79.18 | $839.5K | Form 4 |
| 2026-06-25 | Monia Brett P | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 21,072 | — | $0 | Form 4 |
| 2026-06-25 | Monia Brett P | Director, Officer (Chief Executive Officer) | Open-market sale | 21,072 | $78.49 | $1.65M | Form 4 |
| 2026-06-25 | Monia Brett P | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 21,072 | $32.60 | $686.9K | Form 4 |
| 2026-06-24 | Monia Brett P | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 14,565 | — | $0 | Form 4 |
| 2026-06-24 | Monia Brett P | Director, Officer (Chief Executive Officer) | Open-market sale | 14,565 | $78.41 | $1.14M | Form 4 |
| 2026-06-24 | Monia Brett P | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 14,565 | $32.60 | $474.8K | Form 4 |
| 2026-06-15 | BERTHELSEN SPENCER R | Director | Option exercise / conversion (derivative) | 8,000 | — | $0 | Form 4 |
| 2026-06-15 | BERTHELSEN SPENCER R | Director | Open-market sale | 8,000 | $73.49 | $587.9K | Form 4 |
| 2026-06-15 | BERTHELSEN SPENCER R | Director | Option exercise / conversion | 8,000 | $24.42 | $195.4K | Form 4 |
| 2026-06-12 | Kordasiewicz Holly B. | Officer (EVP, Chief Development Officer) | Option exercise / conversion (derivative) | 21,000 | — | $0 | Form 4 |
| 2026-06-12 | Kordasiewicz Holly B. | Officer (EVP, Chief Development Officer) | Option exercise / conversion (derivative) | 7,951 | — | $0 | Form 4 |
| 2026-06-12 | Kordasiewicz Holly B. | Officer (EVP, Chief Development Officer) | Option exercise / conversion (derivative) | 19,895 | — | $0 | Form 4 |
| 2026-06-12 | Kordasiewicz Holly B. | Officer (EVP, Chief Development Officer) | Option exercise / conversion (derivative) | 12,000 | — | $0 | Form 4 |
| 2026-06-12 | Kordasiewicz Holly B. | Officer (EVP, Chief Development Officer) | Open-market sale | 19,842 | $74.05 | $1.47M | Form 4 |
| 2026-06-12 | Kordasiewicz Holly B. | Officer (EVP, Chief Development Officer) | Open-market sale | 41,004 | $73.09 | $3.00M | Form 4 |
| 2026-06-12 | Kordasiewicz Holly B. | Officer (EVP, Chief Development Officer) | Option exercise / conversion | 19,895 | $56.78 | $1.13M | Form 4 |
| 2026-06-12 | Kordasiewicz Holly B. | Officer (EVP, Chief Development Officer) | Option exercise / conversion | 12,000 | $32.60 | $391.2K | Form 4 |
| 2026-06-12 | Kordasiewicz Holly B. | Officer (EVP, Chief Development Officer) | Option exercise / conversion | 21,000 | $60.89 | $1.28M | Form 4 |
| 2026-06-12 | Kordasiewicz Holly B. | Officer (EVP, Chief Development Officer) | Option exercise / conversion | 7,951 | $60.89 | $484.1K | Form 4 |
| 2026-06-04 | HANTSON LUDWIG | Director | Grant / award / vesting (derivative) | 10,753 | — | $0 | Form 4 |
| 2026-06-04 | Reikes Peter N | Director | Grant / award / vesting (derivative) | 10,753 | — | $0 | Form 4 |
| 2026-06-01 | BERTHELSEN SPENCER R | Director | Option exercise / conversion (derivative) | 8,000 | — | $0 | Form 4 |
| 2026-06-01 | BERTHELSEN SPENCER R | Director | Open-market sale | 8,000 | $75.67 | $605.4K | Form 4 |
| 2026-06-01 | BERTHELSEN SPENCER R | Director | Option exercise / conversion | 8,000 | $24.42 | $195.4K | Form 4 |
| 2026-05-14 | Monia Brett P | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 3,220 | — | $0 | Form 4 |
| 2026-05-14 | Monia Brett P | Director, Officer (Chief Executive Officer) | Open-market sale | 3,220 | $78.68 | $253.3K | Form 4 |
| 2026-05-14 | Monia Brett P | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 3,220 | $32.60 | $105.0K | Form 4 |
| 2026-05-13 | Monia Brett P | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 1,316 | — | $0 | Form 4 |
| 2026-05-13 | Monia Brett P | Director, Officer (Chief Executive Officer) | Open-market sale | 1,316 | $78.01 | $102.7K | Form 4 |
| 2026-05-13 | Monia Brett P | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 1,316 | $32.60 | $42.9K | Form 4 |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Option exercise / conversion (derivative) | 16,000 | — | $0 | Form 4 |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Option exercise / conversion (derivative) | 12,000 | — | $0 | Form 4 |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Option exercise / conversion (derivative) | 16,000 | — | $0 | Form 4 |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Option exercise / conversion (derivative) | 10,321 | — | $0 | Form 4 |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Option exercise / conversion (derivative) | 12,000 | — | $0 | Form 4 |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Option exercise / conversion (derivative) | 10,968 | — | $0 | Form 4 |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Open-market sale | 17,781 | $75.58 | $1.34M | Form 4 |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Open-market sale | 59,508 | $74.90 | $4.46M | Form 4 |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Option exercise / conversion | 16,000 | $64.80 | $1.04M | Form 4 |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Option exercise / conversion | 12,000 | $60.20 | $722.4K | Form 4 |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Option exercise / conversion | 16,000 | $42.88 | $686.1K | Form 4 |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Option exercise / conversion | 10,321 | $41.08 | $424.0K | Form 4 |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Option exercise / conversion | 12,000 | $40.05 | $480.6K | Form 4 |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Option exercise / conversion | 10,968 | $38.06 | $417.4K | Form 4 |
| 2026-05-01 | KLEIN JOSEPH III | Director | Option exercise / conversion (derivative) | 10,111 | — | $0 | Form 4 |
| 2026-05-01 | KLEIN JOSEPH III | Director | Open-market sale | 1,431 | $74.45 | $106.5K | Form 4 |
| 2026-05-01 | KLEIN JOSEPH III | Director | Open-market sale | 8,680 | $73.35 | $636.7K | Form 4 |
| 2026-05-01 | KLEIN JOSEPH III | Director | Option exercise / conversion | 10,111 | $47.11 | $476.3K | Form 4 |
| 2026-04-28 | Baroldi Joseph | Officer (EVP, Chief Business Officer) | Open-market sale | 1,626 | $71.79 | $116.7K | Form 4 |
Ask the chat about IONS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Ionis Pharmaceuticals (IONS).
Last updated 2026-08-31 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.